Universität zu Köln

Holzinger, Astrid, Barden, Markus and Abken, Hinrich (2016). The growing world of CAR T cell trials: a systematic review. Cancer Immunol. Immunother., 65 (12). S. 1433 - 1451. NEW YORK: SPRINGER. ISSN 1432-0851

Full text not available from this repository.

Abstract

In recent years, cancer treatment involving adoptive cell therapy with chimeric antigen receptor (CAR)-modified patient's immune cells has attracted growing interest. Using gene transfer techniques, the patient's T cells are modified ex vivo with a CAR which redirects the T cells toward the cancer cells through an antibody-derived binding domain. The T cells are activated by the CAR primary signaling and costimulatory domains. Such second generation CAR T cells induced complete remission of B cell malignancies in the long-term. In this fast-moving field with a growing number of engineered T cell products, we list about 100 currently ongoing trials here that involve CAR T cells targeting hematopoietic malignancies and solid cancer. Major challenges in the further development of the therapy are briefly discussed.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Holzinger, Astrid UNSPECIFIED UNSPECIFIED UNSPECIFIED Barden, Markus UNSPECIFIED UNSPECIFIED UNSPECIFIED Abken, Hinrich UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-254676
DOI:	10.1007/s00262-016-1895-5
Journal or Publication Title:	Cancer Immunol. Immunother.
Volume:	65
Number:	12
Page Range:	S. 1433 - 1451
Date:	2016
Publisher:	SPRINGER
Place of Publication:	NEW YORK
ISSN:	1432-0851
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CHIMERIC-ANTIGEN-RECEPTOR; CYTOKINE RELEASE SYNDROME; CLINICAL-TRIAL; ADOPTIVE IMMUNOTHERAPY; CD28 COSTIMULATION; ADVERSE EVENT; STEM-CELLS; THERAPY; MALIGNANCIES; PERSISTENCE Multiple languages Oncology; Immunology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/25467